Takamitsu Maru is responsible for efficacy pharmacology in PRISM BioLab. He has a long experience of compound screening and evaluation for about 20 years at Takeda Pharma and Axcelead DDP. From 2025, he joined PRISM BioLab. Especially, he had contributed to making drug discovery research efficient by developing the preparing method of membrane proteins and the binding assay using mass spectrometry before entering Prism BioLab. Now, he is dedicated to finding lead compounds by utilizing the specialty of biochemistry and biophysics. He received his master’s degree from Tohoku University.